Mesa Labs Q3 revenue down 1.5%; operating loss of $67K; core organic revenue declines 9%

MESA LABORATORIES INC /CO/

2024-Q3 EPS reported $0.06 revenue$157,283,000

Revenue $53.5M, down 1.5% YoY; core organic revenue declined 9%.
Operating loss of $67K vs income $3.2M prior year; net income $2.1M up 369% on unusual items.
Non-GAAP adjusted operating income excl. unusual items $12.0M, down 6.8% YoY but up 7.3% sequentially.
Clinical Genomics down 19% on China anti-corruption; Biopharm capital constrained but consumables +16.5%.
Calibration Solutions revenue +12.9%, gross margin +600 bps; GKE acquisition added $3.8M revenue.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MESA LABORATORIES INC /CO/ reported third fiscal quarter ended December 31, 2023 results: revenue $53,473, net income $2,116, EPS $0.39 per diluted share of common stock.

Period: third fiscal quarter ended December 31, 2023
Revenue: $53,473
Net income: $2,116
EPS: $0.39 per diluted share of common stock
Result: reported results

Exact text from the filing

● Non-GAAP adjusted operating income excluding unusual items as a percentage of revenues increased sequentially to 22.4% Executive Commentary (amounts in thousands) “Revenues of $53,473 for the quarter decreased 1.5% as compared to the third quarter of fiscal year 2023 (“3Q23”), due primarily to a 9.0% core organic revenues (“core organic”) decrease which was

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR

accession 0001437749-24-003052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.